Reference ranges for serum S100B protein during the first three years of life

Damien Bouvier1, Christoph Castellani, Mathilde Fournier

  • 1Clermont-Ferrand Teaching Hospital, Biochemistry Department, Clermont-Ferrand, France.

Insights

This study establishes blood S100B reference ranges for children under 3 years, aiding traumatic brain injury diagnosis. These findings offer crucial data for pediatric clinical management.

Area of Science:

  • Pediatric Medicine
  • Biomarker Research
  • Neurology

Background:

  • Traumatic brain injuries (TBIs) pose diagnostic challenges in young children.
  • S100B is a well-established biomarker for TBIs.
  • Establishing age-specific reference ranges is critical for accurate interpretation.

Purpose of the Study:

  • To determine blood S100B reference ranges in healthy children aged 0-3 years.
  • To facilitate the clinical and diagnostic management of TBIs in this pediatric population.
  • To provide a foundational dataset for future TBI research in young children.

Main Methods:

  • Serum S100B concentrations were measured using electro-chemiluminescence immunoassay.
  • A cohort of 186 healthy children aged 0-3 years was analyzed.
  • Data were stratified into four age groups: 0-3, 4-9, 10-24, and 25-36 months.

Main Results:

  • Defined S100B reference ranges for four distinct pediatric age cohorts.
  • Identified an inverse correlation between S100B levels and head circumference.
  • The study represents the largest cohort to date for S100B values in healthy children aged 0-3 years.

Conclusions:

  • This research provides essential serum S100B values for healthy children aged 0-3 years.
  • The established ranges support improved diagnostic accuracy for TBIs in young children.
  • The findings contribute valuable data for pediatric clinical practice and TBI management.
Abstract